Skip to content

Effect of nasal spray dexmedetomidine on postpartum depression: a randomized, double-blind, controlled clinical study

Effect of nasal spray dexmedetomidine on postpartum depression: a randomized, double-blind, controlled clinical study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095334
Enrollment
Unknown
Registered
2025-01-06
Start date
2025-01-10
Completion date
Unknown
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum depression

Interventions

Dexmedetomidine group:10 minutes (± 5 minutes) after delivery of the fetus, 50ug (0.1ml of dexmedetomidine) is given to the woman nasally.
Normal saline group:10 minutes (±5 minutes) after delivery of the fetus, the same volume of saline spray is given to the mother through the nose.

Sponsors

Third Xiangya Hospital, Central South University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) >= 18 years old; (2) Gestation greater than 28 weeks; (3) No serious cardiovascular and cerebrovascular diseases; (4) The mother can communicate well with the follow-up; (5) Voluntarily participate in this study and sign relevant informed consent. (6) Prenatal EPDS score >= 10 points.

Exclusion criteria

Exclusion criteria: (1) Contraindications and allergies to the use of dexmedetomidine; (2) have unstable mental illness; (3) Severe cardiovascular and cerebrovascular diseases; (4) Unable to understand the language of the follow-up and unable to communicate well; (5) Parturients who are considered by the investigator to be unsuitable for enrollment.

Design outcomes

Primary

MeasureTime frame
Incidence of depression;

Secondary

MeasureTime frame
Incidence of self-injurious thoughts;Sleep quality score;Sedation score;Comparison of Generalized Anxiety Disorder-7 score;

Countries

China

Contacts

Public ContactSaiying Wang

Third Xiangya Hospital, Central South University

1642063442@qq.com+86 158 7485 8486

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026